Ankylosing Spondylitis

Immunology·MeSH: Spondylitis, Ankylosing

Prevalence

310.0 / 100K

Incidence

7.3 / 100K/yr

20 drugs in development·14 companies·7 clinical trials

Drug Pipeline by Phase

Approved(18)

Drug	Company
abrilada	PFIZER INC (PFE)
Brenzys (SB4)	Organon & Co. (OGN)
celecoxib	Aptinyx Inc. (APTX)
celecoxib	Zomedica Corp. (ZOMDF)
celecoxib	Miromatrix Medical Inc. (MIRO)
celecoxib	ACADIA PHARMACEUTICALS INC (ACAD)
celecoxib	AlphaTON Capital Corp (ATON)
Hadlima (SB5)	Organon & Co. (OGN)
indocin	Assertio Holdings, Inc. (ASRT)
indocin	Zyla Life Sciences (ZCOR)
INDOCIN (suppositories and oral suspension)	Assertio Holdings, Inc. (ASRT)
INDOCIN Suppositories	Assertio Holdings, Inc. (ASRT)
indomethacin	Amneal Pharmaceuticals, Inc. (AMRX)
indomethacin	Mylan II B.V. (MYL)
Renflexis (SB2)	Organon & Co. (OGN)
Taltz	ELI LILLY & Co (LLY)
Taltz®	ELI LILLY & Co (LLY)
xeljanz xr	PFIZER INC (PFE)

Phase 2(1)

Drug	Company
eq121	EQRx, Inc. (EQRX)

Preclinical(1)

Drug	Company
TCR-depleting antibody program (ankylosing spondylitis)	Adaptive Biotechnologies Corp (ADPT)

BioSniper tracks 20 drugs in development for Ankylosing Spondylitis across 14 companies.

There are 7 clinical trials targeting Ankylosing Spondylitis tracked by BioSniper.

The estimated prevalence of Ankylosing Spondylitis is approximately 310.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.